ReviewNature reviews. Clinical oncology2014
Current and emerging strategies for the prevention of graft-versus-host disease.
Review in Nature reviews. Clinical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 120 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
120 citing papers in PubMed, 207 citations in OpenAlex.
- Preventive hyperbaric oxygen therapy improves acute graft-versus-host disease by activating the Nrf2/HO-1 pathway.Frontiers in immunology · 2025Trial
- Feasibility of a dietary intervention to modify gut microbial metabolism in patients with hematopoietic stem cell transplantation.Nature medicine · 2023Trial
- Trial
- Tocilizumab, tacrolimus and methotrexate for the prevention of acute graft-Haematologica · 2018Trial
- Higher tacrolimus concentrations early after transplant reduce the risk of acute GvHD in reduced-intensity allogeneic stem cell transplantation.Bone marrow transplantation · 2016Trial
- Low-dose tacrolimus combined with donor-derived mesenchymal stem cells after renal transplantation: a prospective, non-randomized study.Oncotarget · 2016Trial
- A randomized controlled trial of cyclosporine and tacrolimus with strict control of blood concentrations after unrelated bone marrow transplantation.Bone marrow transplantation · 2016Trial
- Lack of a significant pharmacokinetic interaction between maraviroc and tacrolimus in allogeneic HSCT recipients.The Journal of antimicrobial chemotherapy · 2015Trial
- Trial
- Impact of CD34European journal of haematology · 2026Article
- Article
- A digital biomarker dataset from hematopoietic cell transplant caregivers and patients.Scientific data · 2026Article
- Selective Immune Silencing by Targeted TGF-β Agonists.bioRxiv : the preprint server for biology · 2026Article
- Impact of prior solid tumor on outcomes of hematopoietic stem cell transplantation for hematologic malignancies: a propensity score-matched study.Frontiers in immunology · 2026Article
- Intravital Microscopy of Mesenteric and Brain Vessels: A Valuable Tool for Leukocyte Recruitment Evaluation.Methods in molecular biology (Clifton, N.J.) · 2026Article
- Retinoic acid regulates donor myeloid-derived suppressor cell and colonic dendrite cell reconstitution after allogeneic hematopoietic stem cell transplantation in mice.Frontiers in immunology · 2026Article
- Tear fluid derived extracellular vesicles for new biomarker discovery.The ocular surface · 2025Review
- Comparing drug combinations for graft-versus-host disease prophylaxis using the U.S. Food and Drug Administration Adverse Event Reporting System.Clinical transplantation and research · 2025Article
- DHODH inhibition alters T cell metabolism limiting acute graft-versus-host disease while retaining graft-versus-leukemia response.Journal of immunology (Baltimore, Md. : 1950) · 2025Article
- Oral inflammation and microbiome dysbiosis exacerbate chronic graft-versus-host disease.Blood · 2025Article
60 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Graft-versus-host disease (GVHD) represents the most serious and challenging complication of allogeneic haematopoietic stem-cell transplantation (HSCT). New insights on the role of regulatory T-cells, T cells, and antigen-presenting cells have led to an improved understanding of the pathophysiology of GVHD. However, little progress has been made since the introduction of calcineurin-inhibitor-based regimens in the mid-1980s. Despite standard prophylaxis with these regimens, GVHD still develops in approximately 40-60% of recipients. Thus, there is a need for developing newer approaches to mitigate GVHD, which may facilitate the use of allogeneic HSCT for the treatment of a wider range of haematological cancers. We discuss the rationale, clinical evidence, and outcomes of current (and widely employed) strategies for GVHD prophylaxis, namely calcineurin-inhibitor-based regimens (such as cyclosporine or tacrolimus) combined with methotrexate or mycophenolate mofetil. We assess the clinical evidence for emerging approaches in the prevention of GVHD, including therapies targeting T cells or B cells, the use of mesenchymal stem cells, chemo-cytokine antagonists (such as maraviroc, TNF-α inhibitor, IL-2 receptor antagonist, IL-6 inhibitor), and the use of novel molecular regulators that target multiple cell types simultaneously, including atorvastatin, bortezomib, and epigenetic modulators.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.